Drugs / EVER001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05800873 | May 2023 → Sep 2026 overdue | idiopathic membranous glomerulonephritis | Everest Medicines (China) Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07614477 | May 2026 → Dec 2028 expected | IgA glomerulonephritis, focal segmental glomerulosclerosis, minimal change disease | Everest Medicines (China) Co.,Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | Evopoint Biosciences Inc. | 信诺维合作伙伴云顶新耀宣布就希布替尼（XNW1011/EVER001）达成独家授权许可与合作协议 evopointbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVER001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05800873 ↗ |
| Action | Inhibit | “Bruton tyrosine kinase (BTK) inhibitor” NCT05800873 ↗ |
| Route | Oral | “EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.” NCT05800873 ↗ |
| Target | BTK | “Bruton tyrosine kinase (BTK) inhibitor” NCT05800873 ↗ |